Composition, structure and packing
Hard gelatin capsules, № 3, white; content capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 25 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, titanium dioxide (E171), water.
Hard gelatin capsules, № 3, body in white, blue cap, the contents of capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 50 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), quinoline yellow (E104), titanium dioxide (E171), water.
Hard gelatin capsules, № 2, body in white, blue cap, the contents of capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 125 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), titanium dioxide (E171), water.
Hard gelatin capsules, № 0, body white cap, dark blue; content capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 250 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), titanium dioxide (E171), water.
Clinico-pharmacological group
Nootropic drugs.
Pharmacological action
Nootropic drugs. Facilitates GABA-mediated transmission of nerve impulses in the central nervous system (a direct effect on GABA-ergic receptors). Tranquilizing effect is combined with an activating effect. Also has antiplatelet, antioxidant and some anticonvulsant activity.
It improves the functional state of the brain due to the normalization of its metabolism and effects on cerebral blood flow (increases the volume and linear velocity, reduces vascular resistance, improves microcirculation, has antiplatelet effect). Lengthens the latency period and shortens the duration and severity of nystagmus.
No effect on holino-and adrenoreceptors. Reduces vazovegetativnye symptoms (including headaches, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability). In exchange you receive increases physical and mental abilities (attention, memory, speed and accuracy of sensory-motor reactions).
Reduces manifestations of asthenia (state of health improves, increases the interest and initiative (motivation activities)) with no sedation or excitation.
Reduces feelings of anxiety, tension and anxiety, normalizes sleep.
The elderly does not cause CNS depression, muscle-relaxing after-effect often absent.
Pharmacokinetics
Absorption and distribution
Absorption is high.
Good penetrates all body tissues and through the BBB (in the brain tissue penetrates about 0.1% of the administered dose, and in young and elderly to a greater extent). Evenly distributed in the liver and kidneys.
Metabolism and excretion
Metabolised in the liver - 80-95%, metabolites are pharmacologically inactive. Not cumulative.
After 3 h begins with urine, with a concentration in the brain tissue is not reduced and is found even within 6 h. About 5% is excreted in the urine in unchanged form and partly in the bile.
Indications for use of the drug
asthenic and anxious-neurotic condition;
stuttering, tics and enuresis in children;
insomnia and nocturnal anxiety in the elderly;
Meniere's disease;
dizziness associated with dysfunction of the vestibular apparatus of various origins;
prevention of motion sickness when kinetozah;
in complex therapy of alcohol withdrawal syndrome for relief of psychopathological and somatovegetativnyh disorders.
Dosage regimen
The drug is prescribed by mouth after eating. The course of treatment - 2-3 weeks.
Adults and children over 14 years appoint 250-500 mg of 3 (maximum daily dose 2.5 g).
Children aged 3 to 8 years appoint 50-100 mg 3; in age from 8 to 14 years - 250 mg 3 maximum single dose for adults and children over 14 years of age is 750 mg in patients over 60 years - 500 mg in children up to 8 years - 150 mg, in children from 8 to 14 years - 250 mg.
When alcohol withdrawal syndrome appoint 250-500 mg 3 and 750 mg at night, with a gradual decrease in daily dose to normal for adults.
For the treatment of vertigo vestibular dysfunction and Meniere's disease drug is prescribed 250 mg of 3 for 14 days.
For prevention of motion sickness appoint 250-500 mg dose 1 hour prior to expected start rolling or when the first symptoms of seasickness. Step Anvifena increases with increasing dose. When the express manifestation of sea-sickness (vomiting, etc.) Appointment Anvifena ineffective even at doses of 750-1000 mg.
Side effect
From the CNS: drowsiness, increased irritability, agitation, anxiety, dizziness, headache (at first admission).
Other: nausea, allergic reactions.
Contraindications to the use of the drug
Pregnancy
lactation (breastfeeding);
Children under 3 years;
Hypersensitivity to the drug's components.
Precautions should be prescribed medication for erosive and ulcerative lesions of the gastrointestinal tract, liver failure.
Pregnancy and lactation
Use of the drug Anvifen contraindicated during pregnancy and lactation.
Application for violations of liver function
Precautions should be prescribed the drug for hepatic failure
Cautions
Prolonged use is necessary to periodically monitor the performance of liver function and pattern of peripheral blood.
Effects on ability to drive vehicles and management mechanisms
During the period of drug administration should refrain from potentially hazardous activities requiring higher concentration.
Overdose
Symptoms: marked drowsiness, nausea, vomiting, fatty liver (receiving more than 7 g), eosinophilia, decrease blood pressure, renal dysfunction.
Treatment: gastric lavage, activated charcoal method and conduct of symptomatic therapy.
Drug Interactions
Anfiven while the application extends and enhances the action of hypnotic drugs, opioid analgesics, neuroleptics, antiparkinsonian, and anticonvulsants.
To the top
Drug prescription.
Terms and Conditions of storage
List B. The drug should be stored in dry, protected from light, away from children at or above 25 ° C. Expiration -3 years.
Hard gelatin capsules, № 3, white; content capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 25 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, titanium dioxide (E171), water.
Hard gelatin capsules, № 3, body in white, blue cap, the contents of capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 50 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), quinoline yellow (E104), titanium dioxide (E171), water.
Hard gelatin capsules, № 2, body in white, blue cap, the contents of capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 125 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), titanium dioxide (E171), water.
Hard gelatin capsules, № 0, body white cap, dark blue; content capsules - a mixture of powder and / or granules of white or white with a yellowish tint.
1 capsule. aminofenilbutirovoy acid hydrochloride 250 mg.
Excipients: giproloza, colloidal silicon dioxide, lactose, magnesium stearate.
Composition of hard gelatin capsules: gelatin, food coloring azorubin (E122), colorant brilliant blue (E133), titanium dioxide (E171), water.
Clinico-pharmacological group
Nootropic drugs.
Pharmacological action
Nootropic drugs. Facilitates GABA-mediated transmission of nerve impulses in the central nervous system (a direct effect on GABA-ergic receptors). Tranquilizing effect is combined with an activating effect. Also has antiplatelet, antioxidant and some anticonvulsant activity.
It improves the functional state of the brain due to the normalization of its metabolism and effects on cerebral blood flow (increases the volume and linear velocity, reduces vascular resistance, improves microcirculation, has antiplatelet effect). Lengthens the latency period and shortens the duration and severity of nystagmus.
No effect on holino-and adrenoreceptors. Reduces vazovegetativnye symptoms (including headaches, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability). In exchange you receive increases physical and mental abilities (attention, memory, speed and accuracy of sensory-motor reactions).
Reduces manifestations of asthenia (state of health improves, increases the interest and initiative (motivation activities)) with no sedation or excitation.
Reduces feelings of anxiety, tension and anxiety, normalizes sleep.
The elderly does not cause CNS depression, muscle-relaxing after-effect often absent.
Pharmacokinetics
Absorption and distribution
Absorption is high.
Good penetrates all body tissues and through the BBB (in the brain tissue penetrates about 0.1% of the administered dose, and in young and elderly to a greater extent). Evenly distributed in the liver and kidneys.
Metabolism and excretion
Metabolised in the liver - 80-95%, metabolites are pharmacologically inactive. Not cumulative.
After 3 h begins with urine, with a concentration in the brain tissue is not reduced and is found even within 6 h. About 5% is excreted in the urine in unchanged form and partly in the bile.
Indications for use of the drug
asthenic and anxious-neurotic condition;
stuttering, tics and enuresis in children;
insomnia and nocturnal anxiety in the elderly;
Meniere's disease;
dizziness associated with dysfunction of the vestibular apparatus of various origins;
prevention of motion sickness when kinetozah;
in complex therapy of alcohol withdrawal syndrome for relief of psychopathological and somatovegetativnyh disorders.
Dosage regimen
The drug is prescribed by mouth after eating. The course of treatment - 2-3 weeks.
Adults and children over 14 years appoint 250-500 mg of 3 (maximum daily dose 2.5 g).
Children aged 3 to 8 years appoint 50-100 mg 3; in age from 8 to 14 years - 250 mg 3 maximum single dose for adults and children over 14 years of age is 750 mg in patients over 60 years - 500 mg in children up to 8 years - 150 mg, in children from 8 to 14 years - 250 mg.
When alcohol withdrawal syndrome appoint 250-500 mg 3 and 750 mg at night, with a gradual decrease in daily dose to normal for adults.
For the treatment of vertigo vestibular dysfunction and Meniere's disease drug is prescribed 250 mg of 3 for 14 days.
For prevention of motion sickness appoint 250-500 mg dose 1 hour prior to expected start rolling or when the first symptoms of seasickness. Step Anvifena increases with increasing dose. When the express manifestation of sea-sickness (vomiting, etc.) Appointment Anvifena ineffective even at doses of 750-1000 mg.
Side effect
From the CNS: drowsiness, increased irritability, agitation, anxiety, dizziness, headache (at first admission).
Other: nausea, allergic reactions.
Contraindications to the use of the drug
Pregnancy
lactation (breastfeeding);
Children under 3 years;
Hypersensitivity to the drug's components.
Precautions should be prescribed medication for erosive and ulcerative lesions of the gastrointestinal tract, liver failure.
Pregnancy and lactation
Use of the drug Anvifen contraindicated during pregnancy and lactation.
Application for violations of liver function
Precautions should be prescribed the drug for hepatic failure
Cautions
Prolonged use is necessary to periodically monitor the performance of liver function and pattern of peripheral blood.
Effects on ability to drive vehicles and management mechanisms
During the period of drug administration should refrain from potentially hazardous activities requiring higher concentration.
Overdose
Symptoms: marked drowsiness, nausea, vomiting, fatty liver (receiving more than 7 g), eosinophilia, decrease blood pressure, renal dysfunction.
Treatment: gastric lavage, activated charcoal method and conduct of symptomatic therapy.
Drug Interactions
Anfiven while the application extends and enhances the action of hypnotic drugs, opioid analgesics, neuroleptics, antiparkinsonian, and anticonvulsants.
To the top
Drug prescription.
Terms and Conditions of storage
List B. The drug should be stored in dry, protected from light, away from children at or above 25 ° C. Expiration -3 years.
No comments:
Post a Comment